CTLA4 and neoplasm: For example, since fewer CAFs in tumors were correlated with reduced survival, anti‐CTLA4 immunotherapy reversed disease acceleration and prolonged animal survival, which highlighted the potential efficacy of immunotherapy in combination therapies.[150] Therefore, the finely tuned combination therapy for PDAC might bring tremendous therapeutic opportunities while decreasing the risk of tumor metastasis.